Multiple existing studies have manifested that the prevalence of histological NASH with normal ALT in NAFLD patients varies from 10.7 to 59.0%, and the risk of fibrosis stage ≥2 of patients with normal ALT is similar to those with elevated ALT (31–33). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.